Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma
Despite the introduction of novel agents such as proteasome inhibitors, immunomodulatory drugs, and autologous stem cell transplant, multiple myeloma (MM) largely remains an incurable disease. In recent years, monoclonal antibody-based treatment strategies have been developed to target specific surf...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-07-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/9/7/2166 |
| _version_ | 1797562889968549888 |
|---|---|
| author | Xiang Zhou Hermann Einsele Sophia Danhof |
| author_facet | Xiang Zhou Hermann Einsele Sophia Danhof |
| author_sort | Xiang Zhou |
| collection | DOAJ |
| description | Despite the introduction of novel agents such as proteasome inhibitors, immunomodulatory drugs, and autologous stem cell transplant, multiple myeloma (MM) largely remains an incurable disease. In recent years, monoclonal antibody-based treatment strategies have been developed to target specific surface antigens on MM cells. Treatment with bispecific antibodies (bsAbs) is an immunotherapeutic strategy that leads to an enhanced interaction between MM cells and immune effector cells, e.g., T-cells and natural killer cells. With the immune synapse built by bsAbs, the elimination of MM cells can be facilitated. To date, bsAbs have demonstrated encouraging results in preclinical studies, and clinical trials evaluating bsAbs in patients with MM are ongoing. Early clinical data show the promising efficacy of bsAbs in relapsed/refractory MM. Together with chimeric antigen receptor-modified (CAR)-T-cells, bsAbs represent a new dimension of precision medicine. In this review, we provide an overview of rationale, current clinical development, resistance mechanisms, and future directions of bsAbs in MM. |
| first_indexed | 2024-03-10T18:35:12Z |
| format | Article |
| id | doaj.art-09fde1c7ec2b4cfdbc3272f727d34308 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T18:35:12Z |
| publishDate | 2020-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-09fde1c7ec2b4cfdbc3272f727d343082023-11-20T06:15:09ZengMDPI AGJournal of Clinical Medicine2077-03832020-07-0197216610.3390/jcm9072166Bispecific Antibodies: A New Era of Treatment for Multiple MyelomaXiang Zhou0Hermann Einsele1Sophia Danhof2Department of internal medicine II, University Hospital Würzburg, Oberdürrbacher Street 6, D-97080 Würzburg, GermanyDepartment of internal medicine II, University Hospital Würzburg, Oberdürrbacher Street 6, D-97080 Würzburg, GermanyDepartment of internal medicine II, University Hospital Würzburg, Oberdürrbacher Street 6, D-97080 Würzburg, GermanyDespite the introduction of novel agents such as proteasome inhibitors, immunomodulatory drugs, and autologous stem cell transplant, multiple myeloma (MM) largely remains an incurable disease. In recent years, monoclonal antibody-based treatment strategies have been developed to target specific surface antigens on MM cells. Treatment with bispecific antibodies (bsAbs) is an immunotherapeutic strategy that leads to an enhanced interaction between MM cells and immune effector cells, e.g., T-cells and natural killer cells. With the immune synapse built by bsAbs, the elimination of MM cells can be facilitated. To date, bsAbs have demonstrated encouraging results in preclinical studies, and clinical trials evaluating bsAbs in patients with MM are ongoing. Early clinical data show the promising efficacy of bsAbs in relapsed/refractory MM. Together with chimeric antigen receptor-modified (CAR)-T-cells, bsAbs represent a new dimension of precision medicine. In this review, we provide an overview of rationale, current clinical development, resistance mechanisms, and future directions of bsAbs in MM.https://www.mdpi.com/2077-0383/9/7/2166bispecific antibodymultiple myelomarelapserefractoryimmunotherapy |
| spellingShingle | Xiang Zhou Hermann Einsele Sophia Danhof Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma Journal of Clinical Medicine bispecific antibody multiple myeloma relapse refractory immunotherapy |
| title | Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma |
| title_full | Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma |
| title_fullStr | Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma |
| title_full_unstemmed | Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma |
| title_short | Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma |
| title_sort | bispecific antibodies a new era of treatment for multiple myeloma |
| topic | bispecific antibody multiple myeloma relapse refractory immunotherapy |
| url | https://www.mdpi.com/2077-0383/9/7/2166 |
| work_keys_str_mv | AT xiangzhou bispecificantibodiesaneweraoftreatmentformultiplemyeloma AT hermanneinsele bispecificantibodiesaneweraoftreatmentformultiplemyeloma AT sophiadanhof bispecificantibodiesaneweraoftreatmentformultiplemyeloma |